Affiliation:
1. Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine University of Saskatchewan Saskatoon Saskatchewan Canada
Abstract
AbstractObjectiveTo assess the ability of intranasal atipamezole to reverse sedative effects of xylazine in dogs.DesignProspective proof‐of‐concept study.SettingUniversity research laboratory.AnimalSix healthy, staff‐owned dogs.InterventionsDogs were sedated with 1.1 mg/kg of xylazine intravenously. The sedation score of each dog was recorded every 5 minutes until they achieved a sedation score of >13/21 for 3 readings. Once achieved, 0.3 mg/kg of atipamezole was administered intranasally using a mucosal atomization device. Sedation scores continued to be recorded every 5 minutes until successful reversal was achieved (<4/21).Measurements and Main ResultsAverage times to standing and normal wakefulness after administration of intranasal atipamezole were 6 minutes, 30 seconds and 7 minutes, 20 seconds, respectively.ConclusionsIntranasal atipamezole successfully reversed the sedation effects of xylazine. The findings of this study provide justification for future controlled prospective studies into the potential use of intranasal atipamezole in a variety of settings including exposure to xylazine in operational canines as well as bioavailability studies for optimal dosing.
Reference23 articles.
1. The Emerging of Xylazine as a New Drug of Abuse and its Health Consequences among Drug Users in Puerto Rico
2. PayerDE YoungMM Maloney‐HallB et al.Adulterants contaminants and co‐occurring substances in drugs on the illegal market in Canada: an analysis of data from drug seizures drug checking and urine toxicology.Canadian Centre on Substance Use and Addiction;2020.
3. Sedation levels in dogs: a validation study
4. Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis
5. AntonJ.‘Fatal combination’: Animal tranquilizer xylazine linked to 4 Sask. deaths.CBC News. March 4 2021.